A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (Nmdar) Or Anti-Leucine-Rich Glioma-Inactivated 1 (Lgi1) Encephalitis

Protocol No
NEURO-GENENTECH-CIELO
Phase
III
Summary

This project is being done to assess the effects, good or bad, of satralizumab in patients with autoimmune encephalitis.

Description
Satralizumab in NMDAR or LGI1 Enchephalitis
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Brain, Spinal Cord, and Nervous System, Multiple Sclerosis
ClinicalTrials.gov
go to website